HALIFAX, July 3, 2012 /PRNewswire via COMTEX/ --
MedMira Inc., (MedMira)
CA:MIR
+9.09%
, a
developer of rapid diagnostic technology and solutions, announced today
that it has been awarded a U.S. Army Medical Research Acquisition
Activity (USAMRAA) contract to develop and commercialize a rapid test
capable of simultaneous detection of HIV and Hepatitis B and C.
The contract, awarded through a competitive bid process, involves a
two-year base period and a 10-month option with a value of
USD$4,266,144, if all options are exercised. MedMira presented its
technology and multiple rapid test, which met the U.S. Army's advanced
technology readiness level requirements. The Multiplo Rapid
HBV/HIV/HCV Antibody Test resulting from this contract award will be
deployed on the frontlines of military healthcare for use in emergency
screening for transfusion transmitted diseases where no FDA approved
donor screening tests are available. The military could also put the
test to use during pre and post deployment screenings and civilian
disaster relief efforts.
No comments:
Post a Comment